

REVIEW

Open Access



T cell exhaustion: from pathophysiological basics to tumor immunotherapy

Kemal Catakovic^{1,2}, Eckhard Klieser^{2,3}, Daniel Neureiter^{2,3†} and Roland Geisberger^{1,2*†} 

Abstract

The immune system is capable of distinguishing between danger- and non-danger signals, thus inducing either an appropriate immune response against pathogens and cancer or inducing self-tolerance to avoid autoimmunity and immunopathology. One of the mechanisms that have evolved to prevent destruction by the immune system, is to functionally silence effector T cells, termed T cell exhaustion, which is also exploited by viruses and cancers for immune escape. In this review, we discuss some of the phenotypic markers associated with T cell exhaustion and we summarize current strategies to reinvigorate exhausted T cells by blocking these surface markers using monoclonal antibodies.

Keywords: Immunotherapy, PD-1, PD-L1, T cell exhaustion, Cancer

Background

Exhausted T cells can be distinguished from other T cell dysfunctions such as anergy and senescence based on their underlying molecular mechanisms [1]. Whereas anergy is introduced during priming due to the absence of costimulatory signals and senescence is growth arrest after extensive proliferation [2], exhausted T cells arise from cells, which initially gained effector function, but become gradually silenced due to continuous T cell receptor (TCR) stimulation from persistent antigen [3].

T cell exhaustion has been initially observed in mice infected with the lymphocytic choriomeningitis virus (LCMV), where a chronically persistent virus strain rendered virus specific cytotoxic T cells non-functional. Using the same mouse model, reversibility of T cell exhaustion could be demonstrated [4, 5].

Exhausted T cells have also been observed in response to several other virus infections like simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human T lymphotropic virus 1 (HTLV1) [6–15]. However, mice with impeded T cell exhaustion develop severe spontaneous

autoimmune diseases and succumb to fatal CD8 T cell-mediated immune pathologies during early systemic LCMV infection, showing that T cell exhaustion substantially contributes to peripheral tolerance and to moderate immune responses [16, 17]. In line with that, presence of exhausted T cells in patients with autoimmune diseases correlates with favorable prognosis [18]. T cell exhaustion has also been observed in tumor patients, where the exhaustion of tumor specific T cells is suggested to impede clearance of the tumor, thus contributing to tumor immune escape [19–23]. Characteristics of exhaustion are continuous enhancement of T cell dysfunction due to persistent antigen exposure, an increased expression of multiple inhibitory receptors (IR), the progressive loss of effector cytokine secretion (IL-2, Interferon gamma [IFN γ], Tumor necrosis factor alpha [TNF α]), an altered cell metabolism and a markedly different transcriptional profile [20, 21, 23–26]. The gradual dysfunction of exhausted T cells is accompanied by the expression of IRs, which wire inhibitory signals to the nucleus upon interaction with ligands on target cells (Fig. 1 and Table 1). However, recent reports reveal that T cells do not uniformly exhaust during chronic diseases or cancer, but that specific subsets with different memory-like or proliferative potentials emerge upon exposure to persisting antigen [27–29]. As blocking iR/ligand interactions (so called immune checkpoint inhibition) seems an appealing strategy to partially reverse T cell exhaustion and to possibly regain anti-cancer immunity, a set

* Correspondence: r.geisberger@salk.at

†Equal contributors

¹Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Müllner Hauptstrasse 48, Salzburg 5020, Austria

²Salzburg Cancer Research Institute, Salzburg, Austria

Full list of author information is available at the end of the article






Fig. 1 Inhibitory/costimulatory receptors and their corresponding ligands. Schematic overview of inhibitory/ costimulatory receptors expressed by T cells interacting with their counterpart on antigen-presenting cells (APCs) or tumor cells. Additionally, various blocking antibodies against inhibitory receptors or their ligands in clinical trials are depicted with the aim of reversing T cell exhaustion

of most promising inhibitory receptors (although their expression is not exclusively restricted to exhausted T cells) and current approaches to impede their function in context of current cancer therapies are discussed in this review:

Inhibitory receptors associated with T cell exhaustion

Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)

CTLA-4 counteracts the positive signal mediated by CD28 by competing for the same ligands (CD80/86)

Table 1 Expression, ligands and signaling pathways of immune checkpoint molecules (based on [210] and [211])

Immune checkpoint receptors (<i>synonym</i>)	Cellular expression	Ligand	Intracellular motif	Signaling pathways
CTLA-4 (<i>CD152</i>)	T cells	CD80, CD86	YxxM	SHP2, LCK/ZAP70/PI3K PP2A/AKT
PD-1 (<i>CD279</i>)	T cells, B cells, DCs, NKT cells, Monocytes	PD-L1, PD-L2	ITIM, ITSM	SHP1, PI3K/AKT SHP2, LCK/ZAP70/PI3K, RAS
TIGIT (<i>VSIG9, VSTM3</i>)	T cells, NK and NKT cells	CD155, CD112	2 × ITIM	NF-κB, PI3K and MAPK
LAG-3 (<i>CD223</i>)	T cells, B cells, DC, NK cells	MHCII	KIEELE	not determined
2B4 (<i>CD244</i>)	T cells, NK cells, Monocytes, Basophiles	CD2, CD48	ITSM	not determined
BTLA (<i>CD272</i>)	T cells, B cells, DC, Macrophages, Myeloid cells	HVEM, CD80	ITIM, ITSM	SHP1, PI3K/AKT SHP2, LCK/ZAP70/PI3K
TIM3 (<i>HAVCR2</i>)	T cells, B cells, NK cells, NKT cells, DCs, Macrophages	Gal-9	Y235, Y242	PI3K BAT3/LCK
VISTA (PD1-H)	T cells, DCs, Macrophages, Monocytes, Neutrophils	not determined	not determined	not determined
CD96 (Tactile)	T cells, NK cells, Myeloid cells	CD155	ITIM	not determined

with higher affinity [30–32]. CTLA-4 transmits signals by intracellularly binding the phosphatases PP2A and SHP-2. In addition, CTLA-4 is able to entrap its ligands CD80/CD86 by trans-endocytosis followed by degradation [33, 34].

CTLA-4 is up-regulated upon activation on naïve T cells and constitutively expressed on regulatory T cells (Tregs), since CTLA-4 is a transcriptional target of Foxp3, a key transcriptional factor of this subset [35, 36]. The role of CTLA-4 in immune suppression and tolerance has been validated in autoimmune mouse models such as type I diabetes and multiple sclerosis, where CTLA-4 blockade results in increased severity of the inflammatory phenotype [37]. CTLA-4 knockout mice provide additional evidence for its role as negative regulator of the immune response, due to the enhanced lymphoproliferative disorder and multiorgan tissue destruction [38, 39]. Paradoxically, although CTLA-4 decreases effector functions of CD4⁺ and CD8⁺ T cells, it increases the suppressive capacity of Tregs. For example, specific CTLA-4 knockdown or blockade on Tregs results in T cell mediated autoimmune disease and contributes to antitumor immunity. Additionally, CTLA-4 expressing Tregs mediate the downregulation of CD80/CD86 on antigen presenting cells and thereby reduce activation of naïve T cells [40, 41]. In context of cancer, it is suggested that CTLA-4 expression on low-affinity tumor specific T cells attenuates their proliferation which could be possibly overcome by CTLA-4 blockade. In addition, CTLA-4 expression on tumor specific Tregs could contribute to tumor immune escape by increasing the suppressive anti-tumor immunity and by downregulating CD80/CD86 on antigen presenting cells [42].

Thus, CTLA-4 dampens T cell activation, decreases the efficacy of antigen presenting cells to activate T cells and augments Treg mediated immune suppression.

Programmed cell death 1 (PD-1)

Whereas CTLA-4 predominantly regulates initial T cell activation, the inhibitory receptor programmed cell death 1 (PD-1) is dampening effector T cell functions [43, 44]. Transient PD-1 cell surface expression is initiated upon T cell activation, but sustained expression is a characteristic marker of T cell exhaustion [45]. However, recent data show that PD-1 is not required for initiating T cell exhaustion and that absence of PD-1 even promotes accumulation of exhausted CD8⁺ T cells in mice [46]. The intracellular domain consists of an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). PD-1 engagement with its ligand (PD-L1 or PD-L2) results in ITIM/ITSM phosphorylation and subsequent recruitment of the phosphatases SHP1/SHP2, which negatively regulate PI3K/AKT and RAS signaling pathways [47–49]. In addition to CTLA-4 Tregs also express PD-1 on their cell surface [50]. During chronic infections such as

LCMV, two subsets of exhausted T cells have been identified according to their transcriptional profile and expression of the inhibitory receptor PD-1 [51].

T cells with an increase in the transcription factor T-bet and an intermediate expression of PD-1 (T-bet^{high} PD-1^{int}) retain residual secretion of IFN γ , TNF α and a limited proliferation rate. On the contrary, high levels of Eomesodermin (Eomes) and PD-1 (Eomes^{high} PD-1^{high}) exhibited higher Blimp1 and granzyme B production, co-expression of additional inhibitory receptors (CD160, Lag-3, 2B4, Tim-3) and are associated with a severe state of exhaustion, despite of a greater cytotoxic activity compared to T-bet^{high} PD-1^{int} T cells. Additionally, T-bet^{high} PD-1^{int} give rise to Eomes^{high} PD-1^{high} in an antigen driven manner and therefore count as a progenitor subset [51]. However, opposing data show that during chronic infection, a small subset of CD8⁺ T cells which were T cell factor 1 (Tcf1)⁺, PD-1⁺ and Eomes⁺ sustained a memory-like T cell response [28].

The blockade of the PD-1/PD-L1 axes in chronic infected LCMV mice sufficiently induces an antiviral state, by which two subpopulations of CD8 cells were identified. Whereas Eomes^{high} PD-1^{high} T cells exhibit a poor response to PD-1 pathway blockade, T-bet^{high} PD-1^{int} virus specific CD8 T cells efficiently reverse exhaustion and induce protective immunity in vivo suggesting that only a small fraction of exhausted T cells might overcome exhaustion by blocking PD-1 signaling [52].

T cell immunoreceptor with Ig and ITIM domains (TIGIT)

Genome wide search for genes specifically expressed on immune cells and consisting of an extracellular Ig domain, type I transmembrane region together with either ITIMs or immunoreceptor tyrosine-based activation motifs (ITAMs), have revealed the existence of an additional inhibitory receptor namely T cell immunoreceptor with Ig and ITIM domains (TIGIT) [53, 54]. It belongs to the type 1 transmembrane proteins with an cytoplasmatic tail containing an immunoglobulin tail tyrosine (ITT)-like phosphorylation motif and ITIM [55]. Its expression is widely distributed across various T cell subsets including follicular helper T cells (T_{FH}), Tregs, activated/memory T cells, natural killer (NK) and natural killer T (NKT) cells [53, 54, 56]. TIGIT attachment to poliovirus receptors (PVR) CD155/CD112 results in the Grb2 mediated-recruitment of the SHIP1 phosphatase and downstream inhibition of NF- κ B, PI3K and MAPK pathways [57, 58]. PVRs are expressed on APCs, endothelial cells, epithelial cells, but also on a number of tumor cells, which are inducible by Ras activation, Toll-like receptor (TLR) engagement and genotoxic stress [59–64].

Similar to CTLA-4/CD28 interactions, TIGIT shares the same ligands as the costimulatory molecule CD226 and competes for ligation resulting in the inhibition of T

cell activation [65]. Interestingly, TIGIT is also capable of directly preventing the homodimerization of CD226 [65] leading to impaired TIGIT/CD226 balance, which impedes CD8 and NK cell antitumor and antiviral T cell response [66, 67]. Additionally, experiments in CD226 deficient mice showed impaired T cell proliferation, reduced immunological synapse formation and antitumor cytotoxicity [68]. Whereas an agonistic TIGIT antibody decreases T cell activation via CD3/CD28 stimulation, TIGIT knockdown enhances T cell proliferation, effector cytokine production such as IFN γ , IL-2 while decreasing IL-10 levels [69]. Additionally, circulating TIGIT⁺ T_{FH} cells produce higher levels of IL-21 and IL-4 and decreased IFN γ secretion compared to TIGIT⁻ T_{FH} cells promoting the differentiation and activation of B cells upon chronic stimulation [56]. Notably, the transcription factor FoxP3 regulates TIGIT expression and furthermore TIGIT⁺ Tregs exhibit higher suppressive functions compared to TIGIT⁻ Tregs [70, 71]. Besides the expression of additional inhibitory receptors, TIGIT⁺ Tregs are promoting Th2 responses by attenuating the secretion of the pro-inflammatory cytokines IFN γ and IL-17 [71].

Pre-clinical tumor studies showed that the specific co-inhibition of the TIGIT and PD-1 checkpoint axis causes a significant enhancement of anti-melanoma immune responses by increasing the effector function of cytotoxic T cells [72, 73]. Additionally, TIGIT positive tumor infiltrating CD8 T-cells could be detected in other solid-tumor entities such as small-cell lung carcinomas and colorectal carcinomas [65, 74]. Taken together, the combination of an anti-TIGIT and anti-PD-1 therapy could be a promising approach with associated stratified tumor entities in the future.

Lymphocyte-activated gene-3 (LAG-3)

The cell surface protein lymphocyte-activated gene-3 (LAG-3) shows structural homologies to CD4 and binds MHCII with a higher affinity compared to CD4 [75, 76]. LAG-3 was also shown to interact with LSECTin, a surface lectin of the DC-SIGN family which is expressed on dendritic cells and also on tumor tissue [77]. LAG-3 is expressed on various cells such as B-cells, NK-cells, plasmacytoid dendritic cells, activated CD4, Tregs and CD8 T cells [78–81]. In the case of T cells, LAG-3 is transiently expressed upon activation and becomes internalized and degraded in the lysosomal compartments [82]. On the cell surface, LAG-3 co-distributes with TCR-CD3, binds to MHCII and inhibits CD4-dependent downstream signaling via its cytoplasmic KIEELE motif and interestingly, not by disrupting CD4- MHCII engagement [83, 84]. As a result, LAG-3 exhibits a negative impact on T cell activation and effector function in vivo and vitro. Upon LAG-3 blockade in vitro T cell proliferation and cytokine production (mainly Th1 cytokines) increases and LAG-3 deficient T

cells generate a larger pool of memory cells due to a delayed cell cycle arrest [85, 86]. An additional subtype of Tregs has been described coexisting in parallel to the classical CD4⁺Foxp3⁺ Treg cells called type 1 regulatory T cells (Tr1), which are lacking the expression of the transcription factor Foxp3 [87]. Tr1 cells exhibit immunosuppressive functions such as IL-10 and TGF- β secretion, however, LAG-3 blockade results in decreased suppressive activity in vivo and *in vitro* pointing out a role for LAG-3 in Treg induction and expansion [88]. Similar to other exhaustion markers, LAG-3 is up-regulated in cancer and chronic infections. During chronic LCMV infections in mouse models combinatorial blockade of PD-1 and LAG-3 initiates synergistic control of viral load and improves T cell response in vivo [89]. Also various human cancer entities as well as tumor mouse models exhibit co-expression of PD-1 and LAG-3 on tumor-infiltrating T cells (TILs) [90, 91]. Interestingly, single inhibition of either LAG-3 or PD-1 alone does not result in improved control of chronic infection or tumor growth, pointing out the complex interactions among inhibitory receptors, whereby dual blockade synergistically reverses the exhausted phenotype [89, 91].

2B4

The receptor 2B4 (CD244) belongs to the signaling lymphocyte activation molecule (SLAM) subfamily within the immunoglobulin superfamily (IgSV). All members of this family contain two or more immunoreceptor tyrosine-based switch motifs (ITSMs) in their cytoplasmic tail including the receptors CD229, CS1, NTB-A and CD84 [92]. 2B4 is expressed by NK cells, $\gamma\delta$ T cells basophils and monocytes, upon activation on CD8⁺ T cells and binds with high affinity to CD48 on lymphoid and myeloid cells [93–95]. An additional binding partner of CD48 is CD2, which is suggested to contribute to the formation of lipid rafts and provides costimulatory signals [96]. Similar to the situation of TIGIT, 2B4- CD48 interaction exhibits either direct intracellular signaling or disruption of CD2-CD48 engagement. Interestingly, 2B4 is not a simple inhibitory receptor, indeed it can also exert costimulatory functions, depending on various factors. For example, 2B4 expression level, usage of downstream adaptor proteins (SAP or EAT-2) and it depends also on which of the four ITSMs is phosphorylated [97–99].

2B4 is associated with T cell exhaustion. Various studies revealed, that exhausted CD8⁺ T cells exhibit increased 2B4 expression during chronic human diseases such as LCMV, HBV, HCV, HIV and also melanoma [100–105]. Interestingly, the adaptor protein SAP contributes to a positive 2B4 signaling, which is higher expressed in effector T cells compared to exhausted T cells, whereas the exhausted ones display elevated 2B4 levels in chronic LCMV infection [100, 106]. This leads to the suggestion,

that the SAP/2B4 ratio is decreased, contributing to the T cell dysfunction during chronic antigen exposure.

B and T lymphocyte attenuator (BTLA)

The cell surface protein B and T lymphocyte attenuator (BTLA) shares structural similarities with PD-1 and CTLA-4 and is expressed on T cells, B cells, macrophages and mature dendritic cells (DC) [107, 108]. Just like LAG-3, BTLA is transiently up-regulated upon TCR engagement and down-regulated on fully activated T cells, albeit retaining PD-1 and CTLA-4 expression [108]. Interestingly, only Th1 polarized cells maintain BTLA cell surface expression but not Th2 cells [107, 108]. The herpesvirus entry mediator (HVEM), which is expressed on various cell types (DCs, NK cells, T and B cells), binds to BTLA and also to the inhibitory receptor CD160 and the costimulatory receptor LIGHT [109, 110]. BTLA-HVEM engagement in T cells leads to tyrosine phosphorylation on the conserved intracellular ITIM, inducing recruitment of the Src homology domain 2 (SH2)-containing protein tyrosine phosphatases SHP-1 and SHP-2 resulting in diminished CD3-induced secretion of IL-2 and T cell proliferation [108, 111].

Since BTLA is described as an inhibitory receptor, it is associated with peripheral tolerance. BTLA deficient mice develop autoimmune hepatitis-like disease with elevated levels of self antibodies, activated CD4⁺ T cells in the periphery, inflammatory cell infiltration of various organs and reduced survival [112]. Similar results have been achieved by the usage of BTLA-deficient T cells exhibiting increased susceptibility to experimental autoimmune encephalomyelitis EAE [108]. Interestingly, a single administration of agonistic BTLA antibodies at the time of autologous haematopoietic stem cell transplantation prevents the development of graft-versus-host disease by the inhibition of CD4⁺ Foxp3⁻ effector T cell expansion [113]. Furthermore, agonistic BTLA antibodies prolong murine cardiac allograft survival by decreasing IL-2 and IFN γ production and shifting the differentiation towards the Treg phenotype [114]. Additionally to the function as receptor, BTLA can also behave as ligand. This has been proved by several studies, indicating that HVEM elicits pro-survival signal for effector and memory T cells expressing HVEM [115–117].

Overexpression in human cancer [118], especially in hematological tumors [119], is linked to impaired tumor specific T-cell activity [23, 120]. Focusing on malignant melanoma, the triple blockade of PD1, TIM3 and BTLA leads consecutively to an increased expansion, proliferation and cytokine production of tumor-associated antigen-specific CD8⁺ T-cells [121]. Comparably to malignant melanoma, a heterogeneous amount of PD-1, Tim-3, CTLA-4, LAG-3, and BTLA were expressed on intratumoral CD8⁺ T cells from 32 patients with NSCLC. Furthermore, these findings could be linked to progression of

the disease [122]. Interestingly, this investigation could clearly demonstrate, that the expression of these immune checkpoint inhibitors was time-dependent showing an early PD-1 and late LAG-3/BTLA expression [122]. Another study with NSCLS could relate the expression of PD-L1, PD-L2, PD-1, TIM-3, B7-H3, BTLA and CTLA-4 to the carcinogenesis relevant epithelial-mesenchymal transition [123]. In another animal model, investigating thyroid carcinoma, a combination of vaccination with BTLA inhibition lead to tumor regression [124]. Furthermore, it was shown that BTLA plays a role in suppression of tumor-associated antigen-specific CD8⁺ T-cell kind allogeneic stem-cell transplantation [125].

T-cell immunoglobulin and mucin- containing protein 3 (TIM3)

The inhibitory receptor T-cell immunoglobulin and mucin- containing protein 3 (TIM-3) is regulated by the transcription factor T-bet and expressed on various T cell subsets including Th1, CD8⁺, Tregs but also on DCs, macrophages and monocytes [126, 127]. Although TIM-3 is thought to exhibit suppressive functions it does not contain an ITIM motif in its intracellular domain like PD-1 or TIGIT. It binds to the soluble molecule S-type lectin Galectin-9 (Gal-9), which is upregulated by IFN γ leading to the downstream recruitment of the Src family tyrosine kinase Fyn and the p85 phosphatidylinositol 3-kinase (PI3K) adaptor [128, 129]. As a result, Th1 mediated immunity is impaired by reducing IFN γ production, increased apoptosis in Th1 and cytotoxic CD8⁺ T cell in vitro [130, 131]. Other ligands for TIM3 are carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) [132], HMGB1 [133] and phosphatidylserine [134]. In preclinical studies, it could be shown that, blockade of TIM-3 signaling enhances the skewing from Th2 to Th1 subsets, thereby reducing allergen induced airway inflammation. Inhibition of Gal-9 amplifies symptoms of experimental autoimmune encephalomyelitis acute graft-versus host disease and type I diabetes in non-obese (NOD) mice [135–138]. The role of TIM-3 is currently being controversially discussed. Some studies display a negative impact on Th1 and Th17 polarization in vitro, while others suppose that Gal-9 triggers Treg differentiation or inhibits Th17 skewing in a TIM-3 independent manner [139–142]. Antagonistic TIM-3 antibodies increases the secretion of Th1 and Th17 effector cytokine production in vitro, elevated Th1 and Th17 differentiation in vivo and diminishes Treg conversion in vitro and in vivo [138, 143, 144]. TIM-3 expression on CD8⁺T cells is associated with high degree of dysfunction in various chronic infections, but also in lymphoma and melanoma patients [145–148]. As discussed in the last section, antagonizing TIM-3 signaling contributes to tumor regression and control of viral load, which can be potentiated by additional PD-1 blockade [146, 149–151].

V domain Ig suppressor of T cells activation (VISTA)

Cloning of a Treg specific transcript with homology to the Ig superfamily led to the discovery of the V domain Ig suppressor of T cells activation (VISTA) or also known as PD-1 homolog (PD-1H) [152, 153]. This type I transmembrane protein consists of 7 exons and shares 85,6% similarity between human and mouse [153]. Although it is suggested that VISTA shares homology with either PD-1 or PD-L1, it does not contain ITIMs or ITAMs [152, 154]. However, due to the fact that the cytoplasmatic tail contains two protein kinase C binding sites and proline residues, which potentially function as docking sites, VISTA may act as both receptor and ligand such as the inhibitory receptor BTLA [154]. Interestingly, the binding partner of VISTA is still unknown. VISTA expression is not limited to T cells. Indeed, is also expressed by DCs, macrophages, monocytes and neutrophils [152, 153, 155]. Besides CTLA-4, PD-1 and TIGIT, Tregs additionally express VISTA on their cell surface, which is suggested to contribute to Treg differentiation and to their suppressive function. Several studies offer solid evidence for VISTAs immunomodulatory role. Firstly, VISTA-fusion protein promotes Treg differentiation in vitro [155]. Secondly, blockade of VISTA impairs differentiation of tumor-specific Tregs, whereby decreasing Treg-mediated suppression and increases infiltration, proliferation and effector functions of tumor-specific T cells [156]. The role of VISTA as a negative regulator of T cell mediated immune response has been strengthened by the fact that VISTA deficient mice display elevated T cell activation, proliferation, secretion of inflammatory cytokines (IFN γ , TNF α , monocyte chemotactic protein-1 [MCP-1], IL-6), chemokines (interferon gamma induced protein-10 [IP-10], monocyte interferon gamma inducing factor [MIG], MCP-1) and multiorgan chronic inflammation. This inflammatory phenotype is synergistically enhanced by VISTA/PD-1 double knockout. In addition, VISTA single knockout mice exhibit resistance towards transplanted GL261 glioma [154, 157, 158]. Interestingly, compared to CTLA-4 knockout mice, VISTA knockout mice exhibit no signs for severe autoimmunity pointing out, that other inhibitory receptors compensate for loss of VISTA [157]. The role of VISTA in cancer immune evasion has been demonstrated in melanoma mouse models, where anti-VISTA antibody treatment resulted in enhanced effector function of tumor specific T cells and to decreased tumor growth [156].

Preclinical studies with inhibition of VISTA revealed a progression of autoimmune encephalomyelitis [152], whereby graft-versus-host-reaction could be inhibited by VISTA blockade [153]. In murine tumor models (such as fibrosarcoma [152] or melanoma [159]), VISTA blockade could significantly improve clinic-pathological aspects like tumor growth or overall survival rate.

Additionally, this was paralleled by enhanced anti-tumor immunity with increased infiltration, proliferation, and effector function of T-cells [156]. Interestingly, the efficiency of the inhibition of VISTA is independent of missing VISTA expression on the tumor cells, and of the presence of high PD-L1 expression [156, 160].

CD96

CD96 (also known as Tactile (T cell activation, increased late expression)) is beside CD226 one of the ligands of CD155 [161]. The discovery of CD96 upregulation in T cells and NK cells within human tumors led to the hypothesis that the inhibition of the CD155/CD96 could essentially influence the tumor elimination [162]. In particular, CD96^{-/-} mice show increased NK-cell activity in response to immune challenge and significant resistance to cancer [163, 164]. In addition, further studies could highlight the role of CD96 in acute myeloid leukaemia (AML) as well as in congenital disease like C syndrome or opitz trigonocephaly [165, 166]. Furthermore CD96 plays a key role in chronic viral disease induced by Hepatitis B [167] or HIV-1 [168], where investigations could reveal that CD96 expression is pathogenetically linked to disease progression [168].

Clinical trials exploiting reinvigoration of T cells

Although checkpoint inhibition is relatively new, it has become a very attractive single therapy option or a combination partner with other standard care of treatment options. This chapter will summarize in a clear and concise manner recently published clinical trials dealing with checkpoint inhibition (for detailed information see Table 2). To do so, we will concentrate on efficacy and tolerability of the checkpoint inhibitors for CTLA-4, PD-1 and, PD-L1 (Fig. 1), due to the fact that there is too little or even no information about other immune checkpoints in clinical trials at the moment. To anticipate efficacy and possible immune related adverse effects (irAEs), it is important to consider which immune cells and T cell subsets are targeted by the respective therapeutic antibodies. As described in the previous chapters, expression of IRs are not solely restricted to exhausted CD8⁺ T cells but may also be expressed on T helper, Treg or antigen presenting cells which could amplify or impede therapeutic effects. Hence, CTLA-4 and PD-1/PD-L1 specific antibodies differ in their mode of action. Whereas CTLA-4 antibodies lower the threshold for T cell activation (also of low affine tumor specific naive T cells), antibodies targeting the PD-1/PD-L axis aim at regulating effector T cell activity [42, 169]. In that sense, PD-1/PD-L antibodies do not merely target cytotoxic CD8⁺ T cell subsets but can impede tumor specific Tregs, thereby potentiating tumor specific cytolytic attacks [169]. Monoclonal antibodies that pharmaceutically inhibit CTLA-4 are

Table 2 Clinical trials for checkpoint inhibitors alone and compared to standard care of treatment

Agent (inhibited checkpoint)	Setting	Phase	Treatment	Tumor response	OS (PFS) in MO	Toxicity (irAE grade ≥3)	Ref	
Ipilimumab (CTLA-4)	Advanced uveal melanoma	II	Ipilimumab	SD 47%	6.8 (2.8)	Colitis, diarrhea, elevated liver enzymes	[176]	
	After complete resection of advanced melanoma	III	Ipilimumab or placebo after complete resection	NM	(26.7 vs 17.1)	Diarrhea, colitis, rash, pruritus, hypo-phsytitis, elevated liver enzymes	[170]	
	Advanced melanoma	II	Ipilimumab	CR 0% PR 10% SD 10% PD 65%	8.7 (2.7)	Elevated liver enzymes	[205]	
	Relapse of malignancy after allogeneic hematopoietic stemcell transplan-tation	I	Ipilimumab	ORR 6.9% CR 6.9% PR 3.4%	24.7	Arthritis, pneumonitis	[175]	
Treme-limumap (CTLA-4)	Relapsed and refractory B-cell NHL	I	Ipilimumab	NM	NM	Diarrhea, fatigue,	[206]	
	Advanced melanoma	III	Tremeli-mumab vs. standard-of-care chemotherapy	NM	12.6 vs 10.7 (at 6 MO 20.3%vs 18.1%)	Diarrhea, colitis, pruritus, rash	[183]	
	Advanced melanoma	I	Anti-CD40 + Tremeli-mumab	NM	26.1 (2.5)	Diarrhea, colitis, pruritus, rash	[212]	
	Advanced gastric and esophageal adeno-carcinoma	II	Tremeli-mumap	PR 56% SD 22%	4.8 (2.8)	Diarrhea, atrial fibrillation, increased liver enzymes	[177]	
	Advanced (metastatic) colorectal carcinoma	II	Tremeli-mumap	PR 2.2% PD 95.6%	At 1a 4.8 vs 10.7% (at 6 MO 2.3 vs 2.1%)	Diarrhea, fatigue, colitis	[185]	
	Advanced NSCLC	II	Tremeli-mumap vs. best supportive care	PR 48% SD 16.6%	20.9% (34%) at 3 MO	Diarrhea, colitis	[213]	
	HHC and chronic hepatitis C	II	Tremeli-mumap	SD 58.8% PR 17.6%	8.2 (6.5)	Skin rash, diarrhea, syncope, diverticulitis, depression	[179]	
	Advanced malignant mesothelioma	II	Tremeli-mumap	PR 3% SD 38%	11.3	Gastrointes-tinal events, dermatologi-cal events, fever	[214]	
	Nivolumab (PD-1)	Advanced refractory squamous NSCLC	II	Nivolumab 3 mg/kg every 2 weeks until progression	PR 14.5% SD 26% PD 44%	8.2 (1.9); 1a 40.1%	Fatigue, diarrhea, rash pruritus	[196]
		Untreated melanoma (BRAF wild type vs mutated)	I	Nivolumab + Ipilimumab vs Ipilimumab + placebo	WT [BRAF+] ORR 61% vs 11% [3% vs 1%] CR 16% vs 0% [5% vs 0%] PR 28% vs 4% [7% vs 1%] SD 9% vs 13% [5% vs 7%]	NM	Diarrhea rash, fatigue pruritus, elevated liver enzymes	[187]
Untreated melanoma without BRAF mutation		III	Nivolumab vs Dacarbazine	ORR 40,0% vs 13,9%	72.9% vs 42.1% at 1a (5.1 vs 2.2)	Fatigue, pruritus, nausea, diarrhea	[186]	
Advanced Squamous-Cell NSCLC	III	Nivolumab vs Docetaxel	ORR 20 vs 9% CR 1 vs 0% PR 26 vs 12% SD 39 vs 47% PD 56% vs 48%	9.2 vs 6.0 (3.5 vs 2.8)	Fatigue; leukopenia	[191]		

Table 2 Clinical trials for checkpoint inhibitors alone and compared to standard care of treatment (Continued)

Advanced non-Squamous-Cell NSCLC	III	Nivolumab vs Docetaxel	ORR 19% vs 12% CR 4 vs 1% PR 52% vs 35% SD 12.7% vs 21% PD 22.2% vs 14.6%	12.2 vs 9.4 (2.3 vs 4.2)	Fatigue, nausea, diarrhea	[192]
Relapsed or refractory Hodgkin's lymphoma	I	Nivolumab	CR 17% PR 70% SD 13%	NM	Leukopenia, stomatitis increased lipase levels, pancreatitis	[206]
Pretreated advanced NSCLC (s and ns)	I	Nivolumab	ORR 17.1% (16.7% s vs 17.6% ns)	9.9	Rash, Colitis	[190]
Untreated melanoma	III	Nivolumab vs Nivolumab + Ipilimumab vs Ipilimumab	ORR 14.6% vs 19.2% vs 6.3% CR 8.9% vs 11.5% vs 2.2% PR 34.8% vs 46.2% vs 16.8% SD 10.8% vs 13.1% vs 21.9% PD 37.7% vs 22.6% vs 48.9%	11.5 vs 2.9 vs 6.9	Diarrhea, fatigue, pruritus, rash	[188]
Platinum resistant ovarian cancer	II	Ipilimumab	CR 10% PR 5% SD 30% PD 50%	20 (3.5)	Lympho-cytopenia, anemia	[215]
Advanced melanoma after anti CTLA-4 treatment	III	Nivolumab vs investigators choice of chemo	ORR 31.7% vs 10.6% CR 3.3% vs 0% PR 28.3% vs 10.6% SD 23.3% vs 34% PD 35% vs 31.9%	(4.7 vs 4.2)	Anemia, fatigue, vomiting	[189]
Advanced renal cell carcinoma	III	Nivolumab vs Everolimus	ORR 25% vs 5% CR 1% vs <1%	25.0 vs 19.6 (4.6 vs 4.4)	Fatigue, diarrhea, rash	[216]
Advanced NSCLC	I	Pembrolizumab	ORR 19.4%	12.0 (3.7)	Fatigue, rash, diarrhea	[217]
Advanced triple negative breast cancer	Ib	Pembrolizumab	ORR 18.5% CR 3.7% PR 14.8% SD 25.9% PD 48.1%	NM	Anemia, headache,	[218]
Previously treated advanced non-small-cell lung cancer	II/III	Pembrolizumab vs Docetaxel	NM	10.4 vs 12.7 vs 8.5 (3.9 vs 4.0 vs 4.0)	Anemia, headache,	[193]
Advanced melanoma	I	Pembrolizumab	ORR 38.6% vs 28.6%	23 (4)	Anemia, headache,	[194]
Progressive metastatic carcinoma with or without mismatch repair-deficiency	II	Pembrolizumab	ORR 40% vs 78% for mismatch repair-deficient CRC and 0% vs 11% mismatch repair-proficient colorectal cancer	NM	Lympho-penia, anemia, diarrhea, bowel obstruction, elevated liver enzymes	[195]
Advanced melanoma	III	Pembrolizumab vs Ipilimumab	ORR 89.4% vs 96.7% vs 87.9%	At 1a 74.1% vs 68.4% (at 6 MO 47.3%vs 46.4% vs 26.5%)	Lympho-penia, anemia, diarrhea, bowel obstruction, elevated liver enzymes	[219]
Previously treated metastatic urothelial carcinoma	II	Atezoli-zumab	ORR 15% CR 5% PR 10% SD 19% PD 51%	NM	Fatigue, decreased appetite, dyspnoea, anemia, colitis	[202]
Previously treated NSCLC	II	Atezo-lizumab vs Docetaxel	NM	12.6 vs 9.7	Diarrhea, asthenia, neutropenia	[201]

Abbreviations: CR complete response, HCC hepatocellular carcinoma, irAE immune related adverse effects, MO months, NM not mentioned, NSCLC non small cell lung cancer, ORR overall response rate, OS overall survival, PD progressive disease, PFS progression free survival, PR partial response, SD stable disease

ipilimumab and tremelimumab. Used as a single therapy, ipilimumab has mostly been investigated in the setting of malignant melanoma and non Hodgkin lymphomas (NHL). In 2015 Eggermont et al. stated in a phase III clinical trial when ipilimumab is given in an adjuvant manner in previously resected stage III melanoma, it significantly improved recurrence-free survival compared with placebo [170]. In combination with glycoprotein 100 (gp100) vaccination or with radiotherapy, ipilimumab improved overall survival or increased the duration of irradiated tumor response [171–173]. Moreover, in combination with the immunostimulator sargramostim, ipilimumab showed longer overall survival in the same setting [174]. Beasley et al. who treated patients suffering from aggressive NHL with ipilimumab after allogeneic hematopoietic cell transplantation recorded antitumor responses as well [175]. Nevertheless, a phase II clinical trial in 2015 revealed only little clinical activity for ipilimumab when given adjuvant after resection of advanced uveal melanoma [176].

Tremelimumab as well has been investigated not only in the setting of advanced malignant melanoma, but also in a number of other malignancies like advanced adenocarcinomas of the gastrointestinal tract, non small cell lung carcinoma (NSCLC) and hepatocellular carcinoma (HCC) as well as malignant mesothelioma [177–182]. Concerning malignant melanoma, in 2013 Ribas et al. were not able to demonstrate a statistically significant survival advantage for tremelimumab compared to standard-of-care chemotherapy in patients suffering from advanced melanoma [183]. But in combination with high dose interferon- α treatment of malignant melanomas showed significant therapeutic benefit [184]. The clinical phase II studies dealing with adenocarcinomas of the esophagus and the colon showed disappointing response rates, not supporting further investigations [177, 185]. In contrast, tremelimumab showed antitumor and antiviral effects in patients suffering from HCC on the basis of hepatitis C-virus infections [179].

The PD-1 inhibiting agents, Nivolumab and Pembrolizumab, were also used in clinical trials to treat malignant melanoma. In a phase III clinical trial, performed by Robert et al., nivolumab showed significant improvements in overall survival and progression free survival compared with dacarbazine. This trial setting focused on untreated melanoma without BRAF mutation [186]. Additionally, Postow et al. and others demonstrated that the combination of nivolumab and ipilimumab had significant advantages over single nivolumab therapy or placebo alone concerning progression-free survival [187, 188]. Even as a second line therapy nivolumab seems to improve outcome in malignant melanoma. In this phase III trial, ipilimumab pretreated advanced melanoma patients were either treated with nivolumab or investigators choice of chemotherapy. In this setting nivolumab demonstrated higher objective response rates than the

alternative available chemotherapy [189]. In the setting of squamous or non squamous NSCLC, nivolumab seems to improve survival rates in previously heavily treated patients [190]. It even showed a better performance compared to docetaxel [191, 192]. Similar to that, pembrolizumab prolonged overall survival compared to docetaxel in NSCLC in a phase II/III clinical trial [193]. Obviously, patients with malignant melanoma were treated with pembrolizumab in a clinical trial as well. Ribas et al. were able to show that pembrolizumab prolonged progression-free survival and overall survival compared to ipilimumab. In another phase I clinical trial pembrolizumab improved objective response and survival rates [194]. In addition, Le et al. showed another very interesting feature of pembrolizumab. They performed a phase II clinical trial in which they were able to investigate that mismatch-repair deficiency predicted clinical effect of pembrolizumab in patients suffering from colorectal carcinoma [195], implying that response rates and clinical benefit from anti-PD1 therapies is correlating with high non-synonymous mutation load, which associates with the presence of tumor associated neoantigens [195, 196]. It was suggested that there is a general correlation of mutation load within tumor DNA and efficacy of immune checkpoint inhibition, irrespective of targeting PD-1 or its ligand, likely by an increased expression of tumor associated neoantigens [195–197]. While tumors with deficiencies in DNA mismatch-repair were found to have a better response to PD-1 blockade [195], it will certainly be clinically relevant to assess other surrogate markers which predict response to immune checkpoint blockade. These markers could likely be mutations in other DNA repair genes but also expression levels of DNA-mutating enzymes, such as family members of the AID/APOBEC deaminases, which could lead to increased mutation load in tumor DNA [198]. In addition, a similar correlation of treatment response and mutation load has been shown for melanoma patients treated with CTLA-4 [194, 195].

Pidilizumab, another PD-1 inhibitor, was used in a combination therapy in two different phase II clinical studies. Relapsed follicular lymphoma patients treated with pidilizumab in combination with rituximab exhibited an overall response rate of 66% and a complete response rate of 52% [199]. In the setting of diffuse large B cell lymphoma, patients treated with pidilizumab after hematopoietic stem cell transplantation showed an overall response rate of 51% and complete response in 34%, although 37% of patients showed a progressive disease in the same clinical trial [200].

Unlike PD-1 targeting antibodies, the PD-L1 specific antibody atezolizumab is not primarily used in the setting of melanoma. In previously treated NSCLC patients,

Table 3 Clinical trials for checkpoint inhibitors in combination with standard care of treatment

Agent (inhibited check-point)	Setting	Phase	Treatment	Tumor response	OS (PFS) in months	Toxicity irAE grade ≥3	Ref.
Ipilimumab (CTLA-4)	Advanced melanoma	III	Ipilimumab or Ipilimumab + glycoprotein 100 or glycoprotein 100 only	NM	10 vs 10.1 vs 6.4 (2.76 vs 2.86 vs 2.76)	Diarrhea, nausea, constipation, vomiting, abdominal pain	[171]
	Advanced melanoma	Retrospective	Ipilimumab or maintenance + median 30 Gy	NM	9 vs 39	NM	[172]
	Advanced melanoma	Retrospective	Ipilimumab vs Ipilimumab + radiotherapy	NM	10.2 vs 19.6	Rash, colitis, GI, fatigue	[173]
	Advanced melanoma	I	Ipilimumab plus radiotherapy	NM	10.7 (3.8)	Anemia, diarrhea, colitis	[220]
Metastatic melanoma	II	Ipilimumab + sargramostim vs Ipilimumab alone	NM	17.5 vs 12.7 (3.1 vs 3.1)	Diarrhea, rash, colitis, elevated liver enzymes	[174]	
	Metastatic NSCLC	I	Ipilimumab + Paclitaxel vs Ipilimumab + Carboplatin	NM	NM	Adrenal insufficiency, enterocolitis	[221]
Advanced, bone metastasis, castration-resistant prostate cancer	III	Ipilimumab or placebo after 8 Gy	NM	11.2 vs 10.2 (4.0 vs 3.1; at 6 MO 30.7% vs 18.1%)	Diarrhea, colitis	[222]	
	Prostate cancer (PSA-recurrent)	I	Tremeli-mumab + Bicalutamide	NM	NM	Colitis	[208]
Tremelimumab (CTLA-4)	Advanced breast cancer	I	Tremeli-mumab + Exemestane	SD 42%	NM	Diarrhea, rash	[207]
	Metastatic pancreatic cancer	I	Tremeli-mumab + Gemcitabine	PR 10.5%	7.4	Asthenia, nausea, diarrhea	[223]
	Advanced melanoma (or solid tumors)	I	Tremeli-mumab + PF-3512676 (CPG 7909) = Toll like receptor 9 inhibitor	NM	19	Diarrhea, hypophy-sitis, colitis, nausea, vomiting, pruritus, rash, neutropenia, rectal Bleeding	[224]
	Advanced melanoma	II	Trimilimumab + high dose INFalpha (HD)	ORR 24% CR 11% PR 14% SD 38%	21 (6.4)	Diarrhea, colitis, elevated liver enzymes, rash, fatigue, anxiety/depression	[184]
Metastatic renal cell carcinoma	I	Tremeli-mumab + sunitinib	PR 42.8%; SD 9.5%	2.8–18.2MO	Fatigue, mucositis, dypnea	[225]	
	Resected advanced melanoma	II	Adjuvant Nivolumab + multi-peptide vaccine (gp100, MART-1 & NY-ESO-1 with Montanide ISA 51 VG)	NM	At 1a 87% At 2a 82%	Colitis, enteritis, rash, hypokalemia	[226]
Pidilizumab (PD-1)	Relapsed follicular lymphoma	II	Pidilizumab + Rituximab	ORR 66% CR 52% PR 14%	NM	No grade 3 or higher irAE	[199]
	DLBCL	II	Pidilizumab after autologous hematopoietic stem-cell transplan-tation	ORR 51% CR 34% PR 17% SD 37% PD 11%	At 16 MO 0.85% (at 16 MO 0.72%)	Thrombo-cytopenia, anemia, pyrexia, renal failure,	[200]
Atezolizumab (PD-L1)	Microsatellite stable metastatic colorectal cancer	Ib	Combination of cobimetinib and atezolizumab	ORR 17% and 20% in KRAS-mutant tumors	At 6 MO 72%	NM	[203]

Abbreviations: CR complete response, irAE immune related adverse effects, MO months, NM not mentioned, NSCLC non small cell lung cancer, ORR overall response rate, OS overall survival, PD progressive disease, PFS progression free survival, PR partial response, SD stable disease

atezolizumab improved survival compared with docetaxel in correlation with PD-L1 expression in the tumor and in tumor infiltrating immune cells [201]. Similar effects on survival were seen in another study dealing with previously metastatic urothelial carcinoma [202]. In combination with cobimetinib, a selective mitogen activated protein kinase (MAP2K1) inhibitor, atezolizumab ameliorated response rates even in mismatch repair proficient metastatic colorectal cancer [203].

Regarding the immune related adverse events of checkpoint inhibitors, all mentioned antibodies show similar immune related adverse events (irAEs, see Tables 2 and 3). Adverse events of grade 3 or higher affected most of the gastrointestinal tract, the skin, the liver function and the hematopoietic system (for more details see Tables 2 and 3). Diarrhea or colitis was observed in almost all clinical trials. However, the majority of adverse events were acceptable and mostly easy to manage [204–206]. Compared to standard chemotherapy, some investigators stated a much better tolerability for checkpoint inhibitors [189, 192, 201]. Moreover, a combination of checkpoint inhibition with ipilimumab and radiotherapy did not show an increase in adverse events [172]. Furthermore, clinical trials investigating combination therapies with standard of care therapies like exemestane in breast cancer, bicalutamide in prostate cancer, rituximab in follicular lymphoma or gemcitabine in pancreatic cancer, showed usually a satisfactory adverse events profile [199, 207–209]).

Conclusions

The results of numerous clinical trials using immune checkpoint inhibitors are very encouraging. Blocking antibodies for CTLA-4, PD-1 or PD-L1 seem to have a strong therapeutic potential when given alone or in combination with standard care of treatment in many different tumor entities. Additionally, checkpoint inhibitors adverse events profiles do not seem to be much worse than profiles of standard chemotherapies, but due to the fact that recently published clinical trials were in phase I or II, these encouraging data needs to be verified in more phase III clinical trials with longer follow up and larger numbers of patients. In addition, future challenges will be to elucidate proper pretreatments or combination therapies to increase clinical benefit of checkpoint inhibition also in cancer with initial low non-synonymous mutation load or low neoantigen expression.

Abbreviations

AKT: proteinkinase B; BTLA: B and T lymphocyte attenuator; CR: complete response; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; EAE: experimental autoimmune encephalomyelitis; Eomes: eomesodermin; Gal-9: galectin-9; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; HTLV1: human T lymphotropic virus 1; HVEM: herpesvirus entry mediator; IgSV: immunoglobulin superfamily;

IR: inhibitory receptor; irAE: immune related adverse effects; ITAM: immunoreceptor tyrosine-based activation motif; ITIM: immunoreceptor tyrosine-based inhibitory motif; ITSM: immunoreceptor tyrosine-based switch motif; ITT: immunoglobulin tail tyrosine; LAG-3: lymphocyte-activated gene-3; LCMV: lymphocytic choriomeningitis virus; MO: months; NHL: non Hodgkin lymphoma; NK: natural killer cell; NKT: natural killer T cell; NM: not mentioned; NOD: non-obese diabetic; NSCLC: non small cell lung cancer; NSCLC: non-small cell lung cancer; ORR: overall response rate; OS: overall survival; PD: progressive disease; PD-1: programmed cell death 1; PD-1H: PD-1 homolog; PD-L1: programmed cell death-ligand 1; PD-L2: programmed cell death-ligand 1; PFS: progression free survival; PI3K: phosphatidylinositide 3-kinases; PR: partial response; PVR: poliovirus receptors; SD: stable disease; SiV: simian immunodeficiency virus; SLAM: signaling lymphocyte activation molecule; T-bet: T-box transcription factor TBX21; TCR: T cell receptor; T_{FH}: follicular helper T cells; TIGIT: T cell immunoreceptor with Ig and ITIM domains; TILs: tumor-infiltrating T cell; TIM-3: T-cell immunoglobulin and mucin- containing protein 3; TLR: toll-like receptor; Tr1: type 1 regulatory T cells; Treg: regulatory T cells; Tregs: regulatory T cells; VISTA: V domain Ig suppressor of T cells activation

Acknowledgements

Not applicable.

Funding

RG receives support from the Austrian science fund FWF, grant P24619 and grant P28201. KC and RG receive support from the LIMCR-SCRI, the province and the city of Salzburg.

Availability of data and materials

Not applicable.

Authors' contributions

CK, EK, DN and RG wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Author details

¹Laboratory for Immunological and Molecular Cancer Research, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University, Müllner Hauptstrasse 48, Salzburg 5020, Austria. ²Salzburg Cancer Research Institute, Salzburg, Austria. ³Department of Pathology, Paracelsus Medical University, Müllner Hauptstrasse 48, Salzburg 5020, Austria.

Received: 31 August 2016 Accepted: 22 December 2016

Published online: 05 January 2017

References

- Crespo J, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. *Curr Opin Immunol.* 2013;25(2):214–21.
- Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res.* 1961;25:585–621.
- Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nat Rev Immunol.* 2015;15(8):486–99.
- Angelosanto JM, et al. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. *J Virol.* 2012; 86(15):8161–70.
- Brooks DG, McGavern DB, Oldstone MB. Reprogramming of antiviral T cells prevents inactivation and restores T cell activity during persistent viral infection. *J Clin Invest.* 2006;116(6):1675–85.
- Day CL, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature.* 2006;443(7109):350–4.

7. Dyavar Shetty R, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. *J Clin Invest*. 2012;122(5):1712–6.
8. Petrovas C, et al. SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection. *Blood*. 2007;110(3):928–36.
9. Yamamoto T, et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. *Blood*. 2011;117(18):4805–15.
10. Gruener NH, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. *J Virol*. 2001;75(12):5550–8.
11. Radziewicz H, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. *J Virol*. 2007;81(6):2545–53.
12. Reignat S, et al. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. *J Exp Med*. 2002;195(9):1089–101.
13. Urbani S, et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. *J Virol*. 2002;76(24):12423–34.
14. Abdelbary NH, et al. Reduced Tim-3 expression on human T-lymphotropic virus type I (HTLV-I) Tax-specific cytotoxic T lymphocytes in HTLV-I infection. *J Infect Dis*. 2011;203(7):948–59.
15. Ezinne CC, et al. HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection. *PLoS One*. 2014;9(2):e87631.
16. Frebel H, et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. *J Exp Med*. 2012;209(13):2485–99.
17. Nishimura H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity*. 1999;11(2):141–51.
18. McKinney EF, et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. *Nature*. 2015;523(7562):612–6.
19. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med*. 2002;8(8):793–800.
20. Fourcade J, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. *J Immunol*. 2009;182(9):5240–9.
21. Gassner FJ, et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. *Haematologica*. 2014;99(5):67–9.
22. Lee PP, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. *Nat Med*. 1999;5(6):677–85.
23. Baitsch L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. *J Clin Invest*. 2011;121(6):2350–60.
24. Gros A, et al. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. *J Clin Invest*. 2014;124(5):2246–59.
25. Radoja S, et al. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. *J Immunol*. 2001;167(9):5042–51.
26. Zenz T. Exhausting T cells in CLL. *Blood*. 2013;121(9):1485–6.
27. Im SJ, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. *Nature*. 2016;537(7620):417–21.
28. Utschneider DT, et al. T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections. *Immunity*. 2016;45(2):415–27.
29. He R, et al. Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection. *Nature*. 2016;537(7620):412–28.
30. Freeman GJ, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. *Science*. 1993;262(5135):909–11.
31. Hathcock KS, et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. *Science*. 1993;262(5135):905–7.
32. Azuma M, et al. B70 antigen is a second ligand for CTLA-4 and CD28. *Nature*. 1993;366(6450):76–9.
33. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. *Immunol Rev*. 2009;229(1):12–26.
34. Qureshi OS, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. *Science*. 2011;332(6029):600–3.
35. Alegre ML, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. *J Immunol*. 1996;157(11):4762–70.
36. Takahashi T, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J Exp Med*. 2000;192(2):303–10.
37. Bour-Jordan H, et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. *Immunol Rev*. 2011;241(1):180–205.
38. Tivol EA, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. *Immunity*. 1995;3(5):541–7.
39. Waterhouse P, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctl4. *Science*. 1995;270(5238):985–8.
40. Wing K, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science*. 2008;322(5899):271–5.
41. Peggs KS, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. *J Exp Med*. 2009;206(8):1717–25.
42. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. *J Leukoc Biol*. 2013;94(1):25–39.
43. Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J*. 1992;11(11):3887–95.
44. Freeman GJ, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med*. 2000;192(7):1027–34.
45. Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*. 2006;439(7077):682–7.
46. Odorizzi PM, et al. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. *J Exp Med*. 2015;212(7):1125–37.
47. Yokosuka T, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. *J Exp Med*. 2012;209(6):1201–17.
48. Parry RV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Mol Cell Biol*. 2005;25(21):9543–53.
49. Patsoukis N, et al. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. *Sci Signal*. 2012;5(230):ra46.
50. Park HJ, et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. *J Immunol*. 2015;194(12):5801–11.
51. Paley MA, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. *Science*. 2012;338(6111):1220–5.
52. Blackburn SD, et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. *Proc Natl Acad Sci U S A*. 2008;105(39):15016–21.
53. Yu X, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. *Nat Immunol*. 2009;10(1):48–57.
54. Stanitsky N, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. *Proc Natl Acad Sci U S A*. 2009;106(42):17858–63.
55. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. *Front Immunol*. 2015;6:418.
56. Godefroy E, et al. TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization. *Haematologica*. 2015;100(11):1415–25.
57. Li M, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/ poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. *J Biol Chem*. 2014;289(25):17647–57.
58. Liu S, et al. Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells. *Cell Death Differ*. 2013;20(3):456–64.
59. Levin SD, et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. *Eur J Immunol*. 2011;41(4):902–15.
60. Carlsten M, et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. *Cancer Res*. 2007;67(3):1317–25.
61. Masson D, et al. Overexpression of the CD155 gene in human colorectal carcinoma. *Gut*. 2001;49(2):236–40.
62. Hirota T, et al. Transcriptional activation of the mouse Necl-5/Tag4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. *Oncogene*. 2005;24(13):2229–35.

63. Kamran N, et al. Toll-like receptor ligands induce expression of the costimulatory molecule CD155 on antigen-presenting cells. *PLoS One*. 2013;8(1), e54406.
64. Soriani A, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. *Blood*. 2009;113(15):3503–11.
65. Johnston RJ, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. *Cancer Cell*. 2014;26(6):923–37.
66. Tahara-Hanaoka S, et al. Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor. *Blood*. 2006;107(4):1491–6.
67. Welch MJ, et al. CD8 T cell defect of TNF-alpha and IL-2 in DNAM-1 deficient mice delays clearance in vivo of a persistent virus infection. *Virology*. 2012;429(2):163–70.
68. Ramsbottom KM, et al. Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display immunological synapse defects that impair antitumor immunity. *J Immunol*. 2014;192(2):553–7.
69. Zhang T, et al. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia. *J Cell Biochem*. 2014;115(11):1918–27.
70. Zhang Y, et al. Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells. *Blood*. 2013;122(16):2823–36.
71. Joller N, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity*. 2014;40(4):569–81.
72. Mahnke K, Enk AH. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention. *J Invest Dermatol*. 2016;136(1):9–11.
73. Inozume T, et al. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. *J Invest Dermatol*. 2016;136(1):255–63.
74. Kurtulus S, et al. TIGIT predominantly regulates the immune response via regulatory T cells. *J Clin Invest*. 2015;125(11):4053–62.
75. Huard B, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. *Eur J Immunol*. 1995;25(9):2718–21.
76. Triebel F, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. *J Exp Med*. 1990;171(5):1393–405.
77. Xu F, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. *Cancer Res*. 2014;74(13):3418–28.
78. Baixeras E, et al. Characterization of the lymphocyte activation gene 3- encoded protein. A new ligand for human leukocyte antigen class II antigens. *J Exp Med*. 1992;176(2):327–37.
79. Huang CT, et al. Role of LAG-3 in regulatory T cells. *Immunity*. 2004;21(4):503–13.
80. Kisielow M, et al. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. *Eur J Immunol*. 2005;35(7):2081–8.
81. Workman CJ, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. *J Immunol*. 2009;182(4):1885–91.
82. Bae J, et al. Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. *J Immunol*. 2014;193(6):3101–12.
83. Hanner S, Triebel F. The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes. *Int Immunol*. 1999;11(11):1745–52.
84. Workman CJ, Dugger KJ, Vignali DA. Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. *J Immunol*. 2002;169(10):5392–5.
85. Macon-Lemaire L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. *Immunology*. 2005;115(2):170–8.
86. Workman CJ, et al. Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo. *J Immunol*. 2004;172(9):5450–5.
87. Groux H, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. *Nature*. 1997;389(6652):737–42.
88. Durham NM, et al. Lymphocyte Activation Gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. *PLoS One*. 2014;9(11), e109080.
89. Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. *Nat Immunol*. 2009;10(1):29–37.
90. Matsuzaki J, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proc Natl Acad Sci U S A*. 2010;107(17):7875–80.
91. Woo SR, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer Res*. 2012;72(4):917–27.
92. McNerney ME, Lee KM, Kumar V. 2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells. *Mol Immunol*. 2005;42(4):489–94.
93. Brown MH, et al. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. *J Exp Med*. 1998;188(11):2083–90.
94. Garni-Wagner BA, et al. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. *J Immunol*. 1993;151(1):60–70.
95. Nakajima H, et al. Activating interactions in human NK cell recognition: the role of 2B4-CD48. *Eur J Immunol*. 1999;29(5):1676–83.
96. Muhammad A, et al. Sequential cooperation of CD2 and CD48 in the buildup of the early TCR signalosome. *J Immunol*. 2009;182(12):7672–80.
97. Chlewicki LK, et al. Molecular basis of the dual functions of 2B4 (CD244). *J Immunol*. 2008;180(12):8159–67.
98. Eissmann P, et al. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). *Blood*. 2005;105(12):4722–9.
99. Bloch-Queyrat C, et al. Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn. *J Exp Med*. 2005;202(1):181–92.
100. Wherry EJ, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. *Immunity*. 2007;27(4):670–84.
101. Raziroouh B, et al. The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. *Hepatology*. 2010;52(6):1934–47.
102. Bengsch B, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. *PLoS Pathog*. 2010;6(6), e1000947.
103. Aldy KN, et al. 2B4+ CD8+ T cells play an inhibitory role against constrained HIV epitopes. *Biochem Biophys Res Commun*. 2011;405(3):503–7.
104. Casado JG, et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. *Cancer Immunol Immunother*. 2005;54(12):1162–71.
105. Enose-Akahata Y, et al. High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease. *PLoS Pathog*. 2009;5(12), e1000682.
106. West EE, et al. Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral load. *Immunity*. 2011;35(2):285–98.
107. Han P, et al. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. *J Immunol*. 2004;172(10):5931–9.
108. Watanabe N, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. *Nat Immunol*. 2003;4(7):670–9.
109. Sedy JR, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. *Nat Immunol*. 2005;6(1):90–8.
110. Cai G, et al. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. *Nat Immunol*. 2008;9(2):176–85.
111. Gonzalez LC, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. *Proc Natl Acad Sci U S A*. 2005;102(4):1116–21.
112. Oya Y, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. *Arthritis Rheum*. 2008;58(8):2498–510.
113. Albring JC, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. *J Exp Med*. 2010;207(12):2551–9.
114. Uchiyama M, et al. An agonistic anti-BTLA mAb (3C10) induced generation of IL-10-dependent regulatory CD4+ T cells and prolongation of murine cardiac allograft. *Transplantation*. 2014;97(3):301–9.
115. Deppong C, et al. B and T lymphocyte attenuator regulates T cell survival in the lung. *J Immunol*. 2008;181(5):2973–9.
116. Steinberg MW, et al. A crucial role for HVEM and BTLA in preventing intestinal inflammation. *J Exp Med*. 2008;205(6):1463–76.

117. Flynn R, et al. CD8 T cell memory to a viral pathogen requires trans costsignaling between HVEM and BTLA. *PLoS One*. 2013;8(10), e77991.
118. Pasero C, et al. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy. *Curr Opin Pharmacol*. 2012;12(4):478–85.
119. M'Hidi H, et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. *Am J Clin Pathol*. 2009;132(4):589–96.
120. Derre L, et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. *J Clin Invest*. 2010; 120(1):157–67.
121. Fourcade J, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. *Cancer Res*. 2012;72(4):887–96.
122. Thommen DS, et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. *Cancer Immunol Res*. 2015;3(12):1344–55.
123. Lou Y, et al. Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. *Clin Cancer Res*. 2016;22(14):3630–42.
124. Lasaro MO, et al. Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. *Mol Ther*. 2011;19(9):1727–36.
125. Hobo W, et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. *J Immunol*. 2012;189(1):39–49.
126. Anderson AC, et al. T-bet, a Th1 transcription factor regulates the expression of Tim-3. *Eur J Immunol*. 2010;40(3):859–66.
127. Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. *Nature*. 2002;415(6871):536–41.
128. Asakura H, et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. *J Immunol*. 2002;169(10):5912–8.
129. Lee J, et al. Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways. *Mol Cell Biol*. 2011;31(19):3963–74.
130. Zhu C, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. *Nat Immunol*. 2005;6(12):1245–52.
131. Sehrawat S, et al. Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. *PLoS Pathog*. 2010;6(5), e1000882.
132. Huang YH, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. *Nature*. 2015;517(7534):386–90.
133. Chiba S, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. *Nat Immunol*. 2012;13(9):832–42.
134. Freeman GJ, et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. *Immunol Rev*. 2010; 235(1):172–89.
135. Kearley J, McMillan SJ, Lloyd CM. Th2-driven, allergen-induced airway inflammation is reduced after treatment with anti-Tim-3 antibody in vivo. *J Exp Med*. 2007;204(6):1289–94.
136. Lee SY, Goverman JM. The influence of T cell Ig mucin-3 signaling on central nervous system autoimmune disease is determined by the effector function of the pathogenic T cells. *J Immunol*. 2013;190(10):4991–9.
137. Veenstra RG, et al. Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. *Blood*. 2012;120(3):682–90.
138. Sanchez-Fueyo A, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. *Nat Immunol*. 2003;4(11):1093–101.
139. He W, et al. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. *Transplantation*. 2009;88(6):782–90.
140. Seki M, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. *Clin Immunol*. 2008;127(1):78–88.
141. Chou FC, et al. Overexpression of galectin-9 in islets prolongs grafts survival via downregulation of Th1 responses. *Cell Transplant*. 2013;22(11):2135–45.
142. Oomizu S, et al. Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. *Clin Immunol*. 2012;143(1):51–8.
143. Boenisch O, et al. TIM-3: a novel regulatory molecule of alloimmune activation. *J Immunol*. 2010;185(10):5806–19.
144. Hastings WD, et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. *Eur J Immunol*. 2009;39(9):2492–501.
145. Golden-Mason L, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. *J Virol*. 2009;83(18):9122–30.
146. Jin HT, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proc Natl Acad Sci U S A*. 2010;107(33):14733–8.
147. Yang ZZ, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. *J Clin Invest*. 2012;122(4):1271–82.
148. Fourcade J, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. *J Exp Med*. 2010;207(10):2175–86.
149. Sakuishi K, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J Exp Med*. 2010;207(10):2187–94.
150. Zhou Q, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. *Blood*. 2011;117(17):4501–10.
151. Takamura S, et al. Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. *J Immunol*. 2010;184(9):4696–707.
152. Wang L, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. *J Exp Med*. 2011;208(3):577–92.
153. Flies DB, et al. Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. *J Immunol*. 2011;187(4):1537–41.
154. Flies DB, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. *J Clin Invest*. 2014;124(5):1966–75.
155. Lines JL, et al. VISTA is an immune checkpoint molecule for human T cells. *Cancer Res*. 2014;74(7):1924–32.
156. Le Mercier I, et al. VISTA Regulates the Development of Protective Antitumor Immunity. *Cancer Res*. 2014;74(7):1933–44.
157. Wang L, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. *Proc Natl Acad Sci U S A*. 2014;111(41):14846–51.
158. Liu J, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. *Proc Natl Acad Sci U S A*. 2015;112(21): 6682–7.
159. Sorensen MR, et al. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. *Vaccine*. 2010;28(41):6757–64.
160. Lines JL, et al. VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy. *Cancer Immunol Res*. 2014;2(6):510–7.
161. Bottino C, et al. Identification of PV9 (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. *J Exp Med*. 2003;198(4):557–67.
162. Fuchs A, et al. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). *J Immunol*. 2004;172(7):3994–8.
163. Chan CJ, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. *Nat Immunol*. 2014;15(5):431–8.
164. Blake SJ, et al. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. *Clin Cancer Res*. 2016;22(21):5183–8.
165. Hosen N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 2007;104(26):11008–13.
166. Kaname T, et al. Mutations in CD96, a member of the immunoglobulin superfamily, cause a form of the C (Opitz trigonocephaly) syndrome. *Am J Hum Genet*. 2007;81(4):835–41.
167. Gong J, et al. Establishment of an enzyme-linked immunosorbent assay system for determining soluble CD96 and its application in the measurement of sCD96 in patients with viral hepatitis B and hepatic cirrhosis. *Clin Exp Immunol*. 2009;155(2):207–15.
168. Eriksson EM, et al. Differential expression of CD96 surface molecule represents CD8(+) T cells with dissimilar effector function during HIV-1 infection. *PLoS One*. 2012;7(12), e51696.
169. He J, et al. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. *Sci Rep*. 2015;5:13110.
170. Eggermont AM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2015;16(5):522–30.

171. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711–23.
172. Barker CA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. *Cancer Immunol Res*. 2013;1(2):92–8.
173. Qin R, et al. Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. *Int J Radiat Oncol Biol Phys*. 2016;96(1):72–7.
174. Hodi FS, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. *JAMA*. 2014; 312(17):1744–53.
175. Bashey A, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. *Blood*. 2009; 113(7):1581–8.
176. Zimmer L, et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. *PLoS One*. 2015; 10(3), e0118564.
177. Ralph C, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. *Clin Cancer Res*. 2010;16(5):1662–72.
178. Antonia S, et al. Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. *Lancet Oncol*. 2016;17(3):299–308.
179. Sangro B, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. *J Hepatol*. 2013;59(1):81–8.
180. Duffy AG, et al. Tremelimumab in Combination with Ablation in Patients with Advanced Hepatocellular Carcinoma. *J Hepatol*. 2016. doi: 10.1016/j.jhep.2016.10.029.
181. Calabro L, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. *Lancet Oncol*. 2013;14(11):1104–11.
182. Guazzelli A, et al. Tremelimumab for the treatment of malignant mesothelioma. *Expert Opin Biol Ther*. 2015;15(12):1819–29.
183. Ribas A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. *J Clin Oncol*. 2013;31(5):616–22.
184. Tarhini AA, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. *J Clin Oncol*. 2012;30(3):322–8.
185. Chung KY, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. *J Clin Oncol*. 2010;28(21): 3485–90.
186. Robert C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med*. 2015;372(4):320–30.
187. Postow MA, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med*. 2015;372(21):2006–17.
188. Larkin J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015;373(1):23–34.
189. Weber JS, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2015;16(4):375–84.
190. Gettinger SN, et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2015;33(18):2004–12.
191. Brahmer J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015;373(2):123–35.
192. Borghaei H, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med*. 2015;373(17):1627–39.
193. Herbst RS, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016;387(10027):1540–50.
194. Ribas A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA*. 2016;315(15):1600–9.
195. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. *N Engl J Med*. 2015;372(26):2509–20.
196. Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science*. 2015; 348(6230):124–8.
197. Roszik J, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med*. 2016;14(1):168.
198. Rebhandl S, et al. AID/APOBEC deaminases and cancer. *Oncoscience*. 2015; 2(4):320–33.
199. Westin JR, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. *Lancet Oncol*. 2014;15(1):69–77.
200. Armand P, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. *J Clin Oncol*. 2013;31(33):4199–206.
201. Fehrenbacher L, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet*. 2016; 387(10030):1837–46.
202. Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet*. 2016;387(10031):1909–20.
203. Bendell JC. Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC - See more at: <http://global.onclive.com/conference-coverage/2016-world-gi/cobimetinib-plus-atezolizumab-active-in-microsatellite-stable-mcrc?p=2#sthash.djKjryZZ.dpuf>. 2016 World Congress on GI Cancer 2016.
204. Rizvi NA, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. *Lancet Oncol*. 2015;16(3):257–65.
205. Yamazaki N, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. *Cancer Chemother Pharmacol*. 2015; 76(5):997–1004.
206. Ansell SM, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*. 2015;372(4):311–9.
207. Vonderheide RH, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. *Clin Cancer Res*. 2010;16(13):3485–94.
208. McNeel DG, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. *Cancer Immunol Immunother*. 2012;61(7):1137–47.
209. Wang-Gillam A, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. *Invest New Drugs*. 2013;31(3):707–13.
210. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013;13(4):227–42.
211. Thaventhiran T, Sethu S, Yeang HXA, Al-Huseini L, Hamdam J, Sathish JG. T Cell Co-inhibitory Receptors: Functions and Signalling Mechanisms. *J Clin Cell Immunol*. 2012;S12:004. doi:10.4172/2155-9899S12-004.
212. Bajor DLM, et al. CT137 - Combination of Agonistic CD40 Monoclonal Antibody CP-870,893 aNM Anti-CTLA-4 Antibody Tremelimumab in Patients with Metastatic Melanoma. Proceedings, Part 2: Clinical Trials aNM Late-Breaking Abstracts. Clinical Trials Plenary Session: Combinations of Therapeutic Agents. AACR. Vol. Part 2. I. Philadelphia, PA: AACR.org; 2015.
213. Zatloukal P, Heo DS, Park K, Kang J, Butts C, Bradford D, Graziano S, Huang B, Healey D. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2009;27(15_suppl):8071.
214. Calabro L, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. *Lancet Respir Med*. 2015;3(4):301–9.
215. Hamanishi J, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. *J Clin Oncol*. 2015;33(34):4015–22.
216. Motzer RJ, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015;373(19):1803–13.
217. Garon EB, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372(21):2018–28.
218. Nanda R, et al. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. *J Clin Oncol*. 2016;34(21):2460–7.

219. Robert C, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2015;372(26):2521–32.
220. Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. 2015; 520(7547):373–7.
221. Horinouchi H, et al. Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. *Invest New Drugs*. 2015;33(4):881–9.
222. Kwon ED, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2014;15(7):700–12.
223. Aglietta M, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naïve patients with metastatic pancreatic cancer. *Ann Oncol*. 2014;25(9):1750–5.
224. Millward M, et al. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. *Br J Cancer*. 2013;108(10):1998–2004.
225. Rini BI, et al. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. *Cancer*. 2011;117(4):758–67.
226. Gibney GT, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. *Clin Cancer Res*. 2015;21(4):712–20.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

